Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 288

1.

Inhibitor sensitivity of human serum and vascular semicarbazide-sensitive amine oxidases.

Mészáros Z, Csányi A, Vallus G, Szombathy T, Karádi I, Magyar K.

Neurobiology (Bp). 2000;8(2):215-23.

PMID:
11061216
2.

Involvement of semicarbazide-sensitive amine oxidase-mediated deamination in atherogenesis in KKAy diabetic mice fed with high cholesterol diet.

Yu PH, Wang M, Deng YL, Fan H, Shira-Bock L.

Diabetologia. 2002 Sep;45(9):1255-62. Epub 2002 Aug 8.

PMID:
12242458
4.

Selective inhibitors of membrane-bound semicarbazide-sensitive amine oxidase (SSAO) activity in mammalian tissues.

Kinemuchi H, Sugimoto H, Obata T, Satoh N, Ueda S.

Neurotoxicology. 2004 Jan;25(1-2):325-35. Review.

PMID:
14697907
6.
9.

Glucose handling in streptozotocin-induced diabetic rats is improved by tyramine but not by the amine oxidase inhibitor semicarbazide.

Visentin V, Bour S, Boucher J, Prévot D, Valet P, Ordener C, Parini A, Carpéné C.

Eur J Pharmacol. 2005 Oct 17;522(1-3):139-46. Epub 2005 Oct 3.

PMID:
16202994
10.
11.

Serum semicarbazide-sensitive amine oxidase (SSAO) activity is an independent marker of carotid atherosclerosis.

Karádi I, Mészáros Z, Csányi A, Szombathy T, Hosszúfalusi N, Romics L, Magyar K.

Clin Chim Acta. 2002 Sep;323(1-2):139-46.

PMID:
12135815
12.

[Determination of serum semicarbazide-sensitive amine oxidase activity in diabetic retinopathy in type-2 diabetes].

Dura E, Mészáros Z, Salacz G, Magyar K, Romics L, Karádi I.

Orv Hetil. 2002 Nov 24;143(47):2637-44. Hungarian.

PMID:
12532650
13.

Anti-inflammatory effects of inhibiting the amine oxidase activity of semicarbazide-sensitive amine oxidase.

Salter-Cid LM, Wang E, O'Rourke AM, Miller A, Gao H, Huang L, Garcia A, Linnik MD.

J Pharmacol Exp Ther. 2005 Nov;315(2):553-62. Epub 2005 Aug 4.

14.

Semicarbazide-sensitive amine oxidase activity in rat aortic cultured smooth muscle cells.

Blicharski JR, Lyles GA.

J Neural Transm Suppl. 1990;32:337-9.

PMID:
2128506
15.

Developmental vasculotoxicity associated with inhibition of semicarbazide-sensitive amine oxidase.

Langford SD, Trent MB, Balakumaran A, Boor PJ.

Toxicol Appl Pharmacol. 1999 Mar 15;155(3):237-44.

PMID:
10079209
16.

Changes in the activities of semicarbazide-sensitive amine oxidase in inferior mesenteric artery segments and in serum of patients with type 2 diabetes.

Nunes SF, Figueiredo IV, Pereira JS, Soares PJ, Caramona MM, Callingham B.

Acta Diabetol. 2010 Jun;47(2):179-82. doi: 10.1007/s00592-009-0174-8. Epub 2010 Jan 9.

PMID:
20063021
17.
18.

Soluble semicarbazide-sensitive amine oxidase (SSAO) activity is related to oxidative stress and subchronic inflammation in streptozotocin-induced diabetic rats.

Somfai GM, Knippel B, Ruzicska E, Stadler K, Tóth M, Salacz G, Magyar K, Somogyi A.

Neurochem Int. 2006 Jun;48(8):746-52. Epub 2006 Mar 9.

PMID:
16524643
19.

Elevated plasma semicarbazide-sensitive amine oxidase (SSAO) activity in Type 2 diabetes mellitus complicated by retinopathy.

Garpenstrand H, Ekblom J, Bäcklund LB, Oreland L, Rosenqvist U.

Diabet Med. 1999 Jun;16(6):514-21.

PMID:
10391401
20.

Diabetes and semicarbazide-sensitive amine oxidase (SSAO) activity: a review.

Obata T.

Life Sci. 2006 Jun 27;79(5):417-22. Epub 2006 Feb 17. Review.

PMID:
16487546

Supplemental Content

Support Center